A Phase 3 Efficacy and Safety Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis

• Conditions: onsense-Mutation-Mediated Cystic Fibrosis; MedDRA version: 9.1Level: LLTClassification code 10011762Term: Cystic fibrosis

• Registration Number: EUCTR2008-003924-52-DE
• Lead Sponsor: PTC Therapeutics, Inc

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2009-07-10
• Last Update Posted: 19 November 2012

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 208

Inclusion Criteria

1. Evidence of signed and dated informed consent/assent document(s) indicating that the subject (and/or parent/legal guardian) has been informed of all pertinent aspects of the study. Note: If the study candidate is considered a child under local regulation, a parent or legal guardian must provide written consent prior to initiation of study screening procedures and the study candidate may be required to provide written assent. The rules of the responsible Institutional Review Board/Institutional Ethics Committee (IRB/IEC) regarding whether one or both parents must provide consent and the appropriate ages for obtaining consent and assent from the subject should be followed.
2. Age =6 years.
3. Body weight =16 kg.
4. Abnormal nasal TEPD total chloride conductance (a less electrically negative value than -5 mV for total chloride conductance [?chloride-free+isoproterenol]). Note: Even if a subject has past documentation of an abnormal TEPD, a TEPD must be performed as part of the screening procedures, must show an adequate tracing in at least 1 nostril, and must be abnormal (taken as a mean of both nostrils if values for both nostrils are available).
5. Sweat chloride >40 mEq/L. Note: A patient does not need to have a repeat sweat test solely for enrollment into this study if documentation of a sweat chloride value>40 mEq/L is already available. However, prior to randomization, all patients must have a baseline sweat chloride test sample collected using study-specific procedures.
6. Documentation of the presence of a nonsense mutation in at least 1 allele of the CFTR gene, as determined by genotyping performed at a laboratory certified by the College of American Pathologists (CAP), or under the Clinical Laboratory Improvement Act/Amendment (CLIA), or by an equivalent organization.
7. Verification that a blood sample has been drawn for sequencing of the CFTR gene. Note: A subject who has written documentation of a nonsense mutation as the cause of CF need not wait for confirmatory results to start study drug as long as the confirmatory blood sample for gene sequencing has been drawn.
8. Ability to perform a valid, reproducible spirometry test using the study-specific spirometer with demonstration of an FEV1 =40% and =90% of predicted for age, gender, and height [Wang 1993, Hankinson 1999].
9. Resting oxygen saturation (as measured by pulse oximetry) =92% on room air.
10. Documentation by VivoMetrics that the subject has satisfactorily completed a 24-hour LifeShirt® cough frequency assessment.
11. Confirmed screening laboratory values within the central laboratory ranges specified in Table 2 below. Note: Confirmation should be performed for out-of-range values to determine if the abnormality is real or artifactual. Values used to establish eligibility should be obtained within the 4-week screening period, and should generally be the most recent measurement obtained.
12. In subjects who are sexually active, willingness to abstain from sexual intercourse or employ a barrier or medical method of contraception during the study drug administration and 4-week follow-up period.
13. Willingness and ability to comply with scheduled visits, drug administration plan, study restrictions, and study procedures (including TEPD testing, spirometry, LifeShirt® evaluations, renal ultrasound, CT scan, and laboratory tests). Note: Psychological, social, familial, or geographical factors that might preclude adequate study participation should be considered.
Are

Exclusion Criteria

1. Known hypersensitivity to any of the ingredients or excipients of the study drug (polydextrose, polyethylene glycol 3350, poloxamer 407, mannitol 25C, crospovidone XL10, hydroxyethyl cellulose, vanilla, colloidal silica, or magnesium stearate).
2. Any change (initiation, change in type of drug, dose modification, schedule modification, interruption, discontinuation, or reinitiation) in a chronic treatment/prophylaxis regimen for CF or for CF-related conditions within 4 weeks prior to start of study treatment. Note: A subject can be enrolled who is using inhaled medications such as aztreonam, tobramycin, dornase-alfa, hypertonic saline, corticosteroids, or ß2 agonists; or systemic drugs such as azithromycin or ibuprofen. Expected cycling of inhaled aztreonam or inhaled tobramycin (or similar inhaled aminoglycoside) is permitted. Other than for treatment of CF pulmonary exacerbations, subjects should remain on a stable medical regimen of treatment/prophylaxis for CF-related conditions to avoid confounding interpretation of study results.
3. Exposure to another investigational drug within 4 weeks prior to start of study treatment. Note: Subjects receiving another investigational drug as part of a pre-approval expanded access program for that drug may participate with the prior consent of the PTC Therapeutics medical monitor.
4. Ongoing participation in any other therapeutic clinical trial. Note: Subjects receiving
another investigational drug as part of a pre-approval expanded access program for that drug may participate with the prior consent of the PTC Therapeutics medical monitor.
5. Treatment with systemic aminoglycoside antibiotics within 2 weeks prior to the date of the baseline TEPD assessment.
6. Treatment with intravenous antibiotics within 3 weeks prior to start of study treatment.
7. Ongoing immunosuppressive therapy (other than corticosteroids).
8. Ongoing warfarin, phenytoin, or tolbutamide therapy.
9. History of solid organ or hematological transplantation.
10. Major complications of lung disease (including massive hemoptysis, pneumothorax, or pleural effusion) within 8 weeks prior to start of study treatment.
11. Evidence of pulmonary exacerbation or acute upper or lower respiratory tract infection (including viral illnesses) within 3 weeks prior to randomization.
12. Known portal hypertension.
13. Positive hepatitis B surface antigen, hepatitis C antibody test, or human immunodeficiency virus (HIV) test.
14. Pregnancy or breast-feeding.
15. Current smoker or a smoking history of =10 pack-years (number of cigarette packs/day × number of years smoked).
16. Prior or ongoing medical condition (eg, concomitant illness, alcoholism, drug abuse, psychiatric condition), medical history, physical findings, ECG findings, or laboratory abnormality that, in the investigator’s opinion, could adversely affect the safety of the subject, makes it unlikely that the course of treatment or follow-up would be completed, or could impair the assessment of study results.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified